secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001493152-26-008475
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioxytran's ProLectin-M achieves 90% Day-5 viral clearance in Phase 1b/2a COVID-19 study
--------------------------------------------------------------------------------

- Phase 1b/2a trial: 39 patients; highest dose 16,800 mg/day showed 90% Day-5 viral clearance vs 20% placebo (p=0.001).
- 90% of highest-dose cohort had ≥2-point improvement on WHO Ordinal Scale by Day 5 vs 20% placebo.
- No serious adverse events, no treatment-related discontinuations; favorable safety profile across all doses.
- ProLectin-M targets galectins to block viral entry; potential broad-range antiviral beyond COVID-19.
- Company plans larger studies to evaluate ProLectin-M as first-line oral antiviral therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000149315226008475/0001493152-26-008475-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000149315226008475/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-008475

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer